Rania A Fahmy1, Naguiba Mahmoud2, Samia Soliman3, Samir R Nouh4, Larry Cunningham5, Ahmed El-Ghannam6. 1. Lecturer, Department of Oral Medicine and Periodontology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. 2. Professor, Department of Oral Medicine and Periodontology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. 3. Professor, Department of Oral Biology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. 4. Professor, Department of Surgery, Faculty of Veterinary Medicine, Alexandria University, Alexandria, Egypt. 5. Professor, Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Kentucky, Lexington, KY. 6. Associate Professor, Department of Mechanical Engineering and Engineering Science, University of North Carolina at Charlotte, Charlotte, NC. Electronic address: arelgha@uncc.edu.
Abstract
PURPOSE: The aim of the present study was to evaluate the effect of a porous silica-calcium phosphate composite (SCPC50) loaded with and without recombinant human bone morphogenetic protein-2 (rhBMP-2) on alveolar ridge augmentation in saddle-type defects. MATERIALS AND METHODS: Micro-granules of SCPC50 resorbable bioactive ceramic were coated with rhBMP-2 10 mg and then implanted into a saddle-type defect (12 × 7 mm) in a dog mandible and covered with a collagen membrane. Control groups included defects grafted with SCPC50 granules without rhBMP-2 and un-grafted defects. Bone healing was evaluated at 8 and 16 weeks using histologic and histomorphometric techniques. The increase in bone height and total defect fill were assessed for each specimen using the ImageJ 1.46 program. The release kinetics of rhBMP-2 was determined in vitro. The height of the bone in the grafted defects and the total defect fill were statistically analyzed. RESULTS: SCPC50 enhanced alveolar ridge augmentation as indicated by the increased vertical bone height, bone surface area, and bone volume after 16 weeks. SCPC50-rhBMP-2 provided a sustained release profile of a low effective dose (BMP-2 4.6 ± 1.34 pg/mL per hour) during the 1- to 21-day period. The slow rate of release of rhBMP-2 from SCPC50 accelerated synchronized complete bone regeneration and graft material resorption in 8 weeks. Successful rapid reconstruction of the alveolar ridge by SCPC50 and SCPC50-rhBMP-2 occurred without any adverse excessive bone formation, inflammation, or fluid-filled voids. CONCLUSIONS: Results of this study suggest that SCPC50 is an effective graft material to preserve the alveolar ridge after tooth extraction. Coating SCPC50-rhBMP-2 further accelerated bone regeneration and a considerable increase in vertical bone height. These findings make SCPC50 the primary choice as a carrier for rhBMP-2. SCPC50-rhBMP-2 can serve as an alternative to autologous bone grafting. Published by Elsevier Inc.
PURPOSE: The aim of the present study was to evaluate the effect of a porous silica-calcium phosphate composite (SCPC50) loaded with and without recombinant humanbone morphogenetic protein-2 (rhBMP-2) on alveolar ridge augmentation in saddle-type defects. MATERIALS AND METHODS: Micro-granules of SCPC50 resorbable bioactive ceramic were coated with rhBMP-2 10 mg and then implanted into a saddle-type defect (12 × 7 mm) in a dog mandible and covered with a collagen membrane. Control groups included defects grafted with SCPC50 granules without rhBMP-2 and un-grafted defects. Bone healing was evaluated at 8 and 16 weeks using histologic and histomorphometric techniques. The increase in bone height and total defect fill were assessed for each specimen using the ImageJ 1.46 program. The release kinetics of rhBMP-2 was determined in vitro. The height of the bone in the grafted defects and the total defect fill were statistically analyzed. RESULTS: SCPC50 enhanced alveolar ridge augmentation as indicated by the increased vertical bone height, bone surface area, and bone volume after 16 weeks. SCPC50-rhBMP-2 provided a sustained release profile of a low effective dose (BMP-2 4.6 ± 1.34 pg/mL per hour) during the 1- to 21-day period. The slow rate of release of rhBMP-2 from SCPC50 accelerated synchronized complete bone regeneration and graft material resorption in 8 weeks. Successful rapid reconstruction of the alveolar ridge by SCPC50 and SCPC50-rhBMP-2 occurred without any adverse excessive bone formation, inflammation, or fluid-filled voids. CONCLUSIONS: Results of this study suggest that SCPC50 is an effective graft material to preserve the alveolar ridge after tooth extraction. Coating SCPC50-rhBMP-2 further accelerated bone regeneration and a considerable increase in vertical bone height. These findings make SCPC50 the primary choice as a carrier for rhBMP-2. SCPC50-rhBMP-2 can serve as an alternative to autologous bone grafting. Published by Elsevier Inc.
Authors: Lara Schorn; Tim Fienitz; Maximilian F Gerstenberg; Anja Sterner-Kock; Alexandra C Maul; Julian Lommen; Henrik Holtmann; Daniel Rothamel Journal: Clin Oral Investig Date: 2021-01-12 Impact factor: 3.573
Authors: Lara Schorn; Christoph Sproll; Michelle Ommerborn; Christian Naujoks; Norbert R Kübler; Rita Depprich Journal: Head Face Med Date: 2017-06-07 Impact factor: 2.151
Authors: Doaa Adel-Khattab; Nermeen S Afifi; Shaimaa M Abu El Sadat; Mona N Aboul-Fotouh; Karim Tarek; Robert A Horowitz Journal: J Periodontal Implant Sci Date: 2020-12 Impact factor: 2.614